Effect of clofibrate on vascular reactivity in a model of high blood pressure secondary to aortic coarctation

Pharmacological Reports

Volumn 62, Issue 5, 2010, Pages 874-882

  Cervantes Pérez, Luz Graciela ^a,b   Ibarra Lara, María De La Luz ^a   Rubio, María Esther ^a   Escalante, Bruno ^b   Pérez Severiano, Francisca ^c   Soria Castro, Elizabeth ^a   Ramírez Ortega, Margarita Del Carmen ^a   Sánchez Mendoza, María Alicia ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Aortic coarctation; Endothelial dysfunction; Hypertension; Nitric oxide; PPAR ; Vascular reactivity

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN I; ANGIOTENSIN II; CLOFIBRATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE; NORADRENALIN; PALMITOYL COENZYME A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA COARCTATION; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME SYNTHESIS; HYPERTENSION; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SYSTOLIC BLOOD PRESSURE; VASOCONSTRICTION; VASODILATATION;

EID: 79551484386     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(10)70347-9     Document Type: Article

References (42)

1. Aird WC: Endothelium in health and disease. Pharmacol Rep, 2008, 60, 139-143.
2. Banks T, Oyekan A: Peroxisome proliferator-activated receptor α activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat. J Hypertens, 2008, 26, 468-477.
3. Barton CH, Ni Z, Vaziri ND: Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int, 2001, 60, 1083-1087.
4. Bell DR, Bohr DF: Endothelium in functional aortic changes of coarctation hypertension. Am J Physiol, 1991, 260, H1187-H1193.
5. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -γ and -β in the adult rat. Endocrinology, 1996, 137, 354-366.
6. Carretero OA, Kuk P, Piwonska S, Houle JA, Marin-Grez M: Role of the renin-angiotensin system in the pathogenesis of severe hypertension in rats. Circ Res, 1971, 29, 654-663.
7. Cheng ZJ, Vapaatalo H, Mervaala E: Angiotensin II and vascular inflammation. Med Sci Monit, 2005, 11, RA194-205.
8. 2+-dependent NOS in renal cortex of ANG II infused hypertensive rats. Am J Physiol, 1999, 277, F797-804.
9. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, Schiffrin EL: PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension, 2002, 40, 866-871.
10. Diep QN, Benkirane K, Amiri F, Cohn JS, Endermann D, Schiffrin EL: PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II infused rats. J Mol Cell Cardiol, 2004, 36, 295-304.
11. Fatehi-Hassanabad Z, Fatehi M, Imen Shahidi M: Endothelial dysfunction in aortic rings and mesenteric beds isolated from deoxycorticosterone acetate hypertensive rats: possible involvement of protein kinase C. Eur J Pharmacol, 2004, 494, 199-204.
12. Fernándes M, Onesti G, Weder A, Dykyj R, Gould AB, Kim KE, Swartz C: Experimental model of severe renal hypertension. J Lab Clin Med, 1976, 87, 561-567.
13. Förstermann U, Boissel JP, Kleinert H: Expressional control of the "constitutive" isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J, 1998, 12, 773-790.
14. Furchgott RF, Vanhoutte PM: Endothelium-derived relaxing and contracting factors. FASEB J, 1989, 3, 2007-2018.
15. González-Barrios JA, Escalante B, Valdés J, León-Chávez BA, Martínez-Fong D: Nitric oxide and nitric oxide synthases in the fetal cerebral cortex of rats following transient uteroplacental ischemia. Brain Res, 2002, 945, 114-122.
16. Goya K, Sumitani S, Xu X, Kitamura T, Yamamoto H, Kurebayashi S, Saito H et al.: Peroxisome proliferator-activated receptor α agonist increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol, 2004, 24, 658-663.
17. Green S: PPAR: a mediator of peroxisome proliferator action. Mutat Res, 1995, 333, 101-109.
18. Han SH, Quon MJ, Koh KK: Beneficial vascular and metabolic effects of peroxisome proliferators-activated receptor-activators. Hypertension, 2005, 46, 1086-1092.
19. Harrison DG: Endothelial function and oxidant stress. Clin Cardiol, 1997, 20, Suppl 2, 11-17.
20. Iglarz M, Touyz RM, Amiri F, Lavoie M-F, Diep QN, Schiffrin EL: Effect of peroxisome proliferator-activated receptor-α and -β activators on vascular remodeling in endothelin-dependent hypertension. Arterioscler Thromb Vasc Biol, 2003, 23, 45-51.
21. Inoue I, Shino K, Noji S, Awata T, Katayama S: Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun, 1998, 246, 370-374.
22. Jonkers IJ, de Man FH, van der Laarse A, Frölich M, Gevers Leuven JA, Kamper AM, Blauw GJ, Smelt AH: Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia. J Hypertens, 2001, 19, 749-755.
23. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W: Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA, 1993, 90, 2160-2164.
24. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II mediated cardiovascular and renal diseases. Pharmacol Rev, 2000, 52, 11-34.
25. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA, 1994, 91, 7355-7359.
26. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL, Fernández-Salguero PM et al.: Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol, 1995, 15, 3012-3022.
27. Li H, Witte K, August M, Brausch I, Gödtel-Armbrost J, Habermeier A, Closs E et al.: Reversal endothelial nitric oxide synthase uncoupling and up-regulation of endothelial nitric oxide synthase expression lowers blood pressure in hypertensive rats. J Am Coll Cardiol, 2006, 47, 2536-2544
28. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem, 1951, 193, 265-275.
29. McGrath JC, Deighan C, Briones AM, Shafaroudi MM, McBride M, Adler J, Arribas SM et al: New aspects of vascular remodelling: the involvement of all vascular cell types. Exp Physiol, 2005, 90, 469-475.
30. Newaz M, Blanton A, Fidelis P, Oyekan A: NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)α- mediated cardiovascular effects. Mutat Res, 2005, 579, 163-171.
31. Quilley J, Bell-Quilley C, McGiff J: Eicosanoids and hypertension. In: Hypertension: pathophysiology, diagnosis and management. Ed. Laragh JH, Brenner BM, Raven Press, New York, 1995, 963-981.
32. Rees DD, Palmer RM, Moncada S: Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA, 1989, 86, 3375-3378.
33. Rubio ME, Bańos G, Díaz E, Guarner V: Effect of age on insulin-induced endothelin release and vasoreactivity in hypertriglyceridemic and hypertensive rats. Exp Gerontol, 2006, 41, 282-288.
34. Sánchez-Mendoza A, Hong E, Escalante B. The role of nitric oxide in angiotensin II-induced renal vasoconstriction in renovascular hypertension. J Hypertens, 1998, 16, 697-703.
35. Sankaralingam S, Desai KM, Wilson TW: Chronic clofibrate administration prevents saline-induced endothelial dysfunction and oxidative stress in young Sprague-Dawley rats. Clin Invest Med, 2008, 31, E62-70.
36. Schoonjans K, Martin G, Staels B, Auwerx J: Peroxisome proliferator activated receptors, orphans with ligands and functions. Curr Opin Lipidol, 1997, 8, 159-166.
37. Schoonjans K, Staels B, Auwerx J: Role of the peroxisome proliferator activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res, 1996, 37, 907-925.
38. Simonsen U, Rodriguez-Rodriguez R, Dalsgaard T, Buus NH, Stankevicius E: Novel approaches to improving endothelium-dependent nitric oxide-mediated vasodilation. Pharmacol Rep, 2009, 61, 105-115.
39. Vera T, Taylor M, Bohman Q, Flasch A, Roman RJ, Stec DE: Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. Hypertension, 2005, 45, 730-735.
40. Walusimbi-Kisitu M, Harrison EH: Fluorometric assay for rat liver peroxisomal fatty acyl-coenzyme A oxidase activity. J Lipid Res, 1983, 24, 1077-1084.
41. Willson TM, Lehmann JM, Kliewer SA: Discovery of ligands for the nuclear peroxisome proliferator-activated receptors. Ann NY Acad Sci, 1996, 804, 276-283.
42. Zalba G, San Jose G, Moreno M, Fortuńo M, Fortuńo A, Beaumont F, Diez J: Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension, 2001, 38, 1395-1399.